More than 45 million people worldwide are estimated to have Alzheimer's disease (AD) or some type of dementia, and there are few therapeutics to help them. Although a handful of high-profile candidates are currently being tested in expensive large-scale clinical trials, the neurodegenerative space is particularly fraught with failure. As problematically, the early-stage pipeline for AD is running dry. So what happens if plan A fails again, as it has so many times in the past? Eric Karran, Director of Research at Alzheimer's Research UK, hopes that the newly launched UK£30-million Drug Discovery Alliance can shore up the community. The former head of neuroscience research at Johnson & Johnson, Eli Lilly and Pfizer tells Asher Mullard about Alzheimer's Research UK's plan to embed drug discovery teams directly into academic centres.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Eric Karran. Nat Rev Drug Discov 14, 230–231 (2015). https://doi.org/10.1038/nrd4584
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4584
